CAMP4 Therapeutics Gets Clearance to Conduct Phase 1/2 Study for SYNGAP1-Related Disorder Treatment in UK

08:06 AM EDT, 09/10/2026 (MT Newswires) -- CAMP4 Therapeutics (CAMP) has received approval from the UK's Medicines and Healthcare Products Regulatory Agency to include sites in the country for its phase 1/2 clinical trial evaluating CMP-002 as a treatment for SYNGAP1-related disorder, a rare central nervous system disorder caused by gene mutations, the drugmaker said Thursday. The company said it recently secured regulatory clearances in Australia and Argentina to begin first-in-human studies for CMP-002, which is on track to start in Q4. CAMP4's regulatory submission to the European Union remains under review, it said.